MKI67 and acinar cell carcinoma: Given a relatively indolent clinical course in a subset of AcCC (e.g., low-grade cases), these patients should probably be spared chemotherapy [43]; similarly, neoadjuvant chemotherapy should not be a preferable option for AcCC patients due to the predominantly low proliferation rate measured by Ki-67 (Table 3).